Items where authors include "Evangelou, N."

Article

Chataway, J., Williams, T., Blackstone, J. et al. (135 more authors) (2025) Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet, 406 (10512). pp. 1611-1624. ISSN 0140-6736

Horne, R.M., Hollomotz, A. orcid.org/0000-0003-3496-3924, Ford, H.L. et al. (5 more authors) (2025) Reader Response: Right Brain: The Unraveling. Neurology, 104 (7). e209834. ISSN 0028-3878

Wood, G.K. orcid.org/0000-0001-6098-2331, Sargent, B.F. orcid.org/0000-0003-2262-7755, Ahmad, Z.-U.-A. orcid.org/0000-0002-6940-8851 et al. (173 more authors) (2025) Posthospitalization COVID-19 cognitive deficits at 1 year are global and associated with elevated brain injury markers and gray matter volume reduction. Nature Medicine, 31. pp. 245-257. ISSN 1078-8956

Blackstone, J., Williams, T., Nicholas, J.M. et al. (59 more authors) (2024) Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK. BMJ Open, 14 (9). e086414. ISSN 2044-6055

John, N., Li, Y., De Angelis, F. et al. (49 more authors) (2024) Brain reserve and physical disability in secondary progressive multiple sclerosis. BMJ Neurology Open, 6 (2). e000670. ISSN 2632-6140

Michael, B.D. orcid.org/0000-0002-8693-8926, Dunai, C. orcid.org/0000-0001-5799-2387, Needham, E.J. orcid.org/0000-0001-7042-7462 et al. (559 more authors) (2023) Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses. Nature Communications, 14 (1). 8487. ISSN 2041-1723